Bayer (XETR:BAYN) Wins FDA Nod Expanding Kerendia to CKD in Type 1 Diabetes
Bayer received FDA approval for Kerendia (finerenone) to reduce UACR, expected to slow CKD progression, in adults with CKD associated with type 1 diabetes.Material DetailsContext by AI AnalystThis is a late-stage confirmation of Bayer’s strategy to broaden Kerendia beyond T2D CKD and HF. For a larg…